🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "huge turning point" in the battle against increasingly resistant strains of the infection, according to researchers.

A Worldwide Challenge

Cases of gonorrhoea are on the rise globally, with figures suggesting in excess of 82 million new cases each year. Notably increased rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an important and timely advancement in the context of rising global incidence, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Medical experts are particularly alarmed about the rise in antibiotic-resistant strains. The World Health Organization has designated it as a "priority pathogen". Recent surveillance showed that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Gain Approval

One new antibiotic, also known as a brand name, was cleared by the US Food and Drug Administration in December for treating gonorrhoea. This infection can lead to significant complications, including infertility. Experts believe that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, gained clearance in the same week. This medication, which is employed against UTIs, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment was the result of a unique collaborative effort for drug creation. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to develop it.

“This authorization marks a significant shift in the treatment of superbug gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Research Study Results and Worldwide Availability

As per data detailed in a major medical journal, the new drug successfully treated more than 90% of genital gonorrhoea infections. This puts it on an comparable level with the typical regimen, which involves an injection and a pill. The trial included over 900 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the rights to license and sell the drug in many low-income and middle-income countries.

Doctors directly involved have shared hope. The availability of a one-pill regimen like this is hailed as a "game-changer" for managing the epidemic. This is viewed as vital to lessen the impact of the illness for people and to halt the transmission of extremely resistant gonorrhoea globally.